Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study of CD19-targeted Chimeric Antigen Receptor (CAR) T Cells Injection, for Relapsed and Refractory (R/R) Large B-cell Lymphoma

NCT05472610 is registered in ClinicalTrials.gov with Shanghai Mengchao Cancer Hospital as lead sponsor.

NCT NCT05472610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05472610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study of CD19-targeted Chimeric Antigen Receptor (CAR) T Cells Injection, for Relapsed and Refractory (R/R) Large B-cell Lymphoma
Lead sponsor
Shanghai Mengchao Cancer Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
June 4, 2021
Completion date
January 31, 2023
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

large b-cell lymphoma